Programming tumor-reactive effector memory CD8+ T cells in vitro obviates the requirement for in vivo vaccination

Blood

Volumn 114, Issue 9, 2009, Pages 1776-1783

  Klebanoff, Christopher A ^a,b   Yu, Zhiya ^b   Hwang, Leroy N ^b   Palmer, Douglas C ^b   Gattinoni, Luca ^b   Restifo, Nicholas P ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIBODY; GAMMA INTERFERON; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MONOCLONAL ANTIBODY CD28; PROTEIN HGP100; RECOMBINANT PROTEIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG; CANCER VACCINE; CD28 ANTIGEN; CD3 ANTIGEN;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD8+ T LYMPHOCYTE; CELL TRANSFER; CONTROLLED STUDY; CYTOLYSIS; FEMALE; IMMUNE RESPONSE; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; MEMORY T LYMPHOCYTE; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL DESTRUCTION; VACCINATION; ANIMAL; BIOSYNTHESIS; CELL SEPARATION; CYTOLOGY; EXPERIMENTAL MELANOMA; FLOW CYTOMETRY; GENE; IMMUNOLOGY; METABOLISM; NEOPLASM; PHENOTYPE; TRANSGENIC MOUSE;

ANIMALS; ANTIGENS, CD28; ANTIGENS, CD3; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL SEPARATION; FLOW CYTOMETRY; GENES, MHC CLASS I; INTERFERON-GAMMA; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA, EXPERIMENTAL; MICE; MICE, TRANSGENIC; NEOPLASMS; PHENOTYPE;

EID: 70349237569     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-12-192419     Document Type: Article

References (56)

1. Leen AM, Rooney CM, Foster AE. Improving T cell therapy for cancer. Annu Rev Immunol. 2007;25:243-265.
2. June CH. Adoptive T cell therapy for cancer in the clinic. J Clin Invest. 2007;117(6):1466-1476. (Pubitemid 46871329)
3. Gattinoni L, Powell DJ Jr, Rosenberg SA, Restifo NP. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol. 2006;6(5):383-393.
4. Kennedy-Nasser AA, Brenner MK. T-cell therapy after hematopoietic stem cell transplantation. Curr Opin Hematol. 2007;14(6):616-624. (Pubitemid 47494077)
5. Levine BL. T lymphocyte engineering ex vivo for cancer and infectious disease. Expert Opin Biol Ther. 2008;8(4):475-489.
6. Caligiuri MA, Velardi A, Scheinberg DA, Borrello IM. Immunotherapeutic approaches for hematologic malignancies. Hematology Am Soc Hematol Educ Program. 2004;337-353.
7. Overwijk WW, Theoret MR, Finkelstein SE, et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med. 2003;198(4):569-580.
8. Lou Y, Wang G, Lizee G, et al. Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo. Cancer Res. 2004; 64(18):6783-6790. (Pubitemid 39297942)
9. Palmer DC, Balasubramaniam S, Hanada K, et al. Vaccine-stimulated, adoptively transferred CD8+ T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction. J Immunol. 2004;173(12):7209-7216. (Pubitemid 39628156)
10. Wang LX, Li R, Yang G, et al. Interleukin-7- dependent expansion and persistence of melanoma- specific T cells in lymphodepleted mice lead to tumor regression and editing. Cancer Res. 2005;65(22):10569-10577. (Pubitemid 41743752)
11. Smith F, Klapper J, Wunderlich J, Rosenberg S, Dudley M. Impact of a recombinant fowlpox vaccine on the efficacy of adoptive cell therapy with tumor infiltrating lymphocytes in a patient with metastatic melanoma. J Immunother. In press.
12. Sikora AG, Jaffarzad N, Hailemichael Y, et al. IFN-alpha enhances peptide vaccine-induced CD8+ T cell numbers, effector function, and antitumor activity. J Immunol. 2009;182(12):7398-7407.
13. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005;23(10):2346-2357.
14. Dudley ME, Yang JC, Sherry R, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008;26(32):5233-5239.
15. Kessler JH, Melief CJ. Identification of T-cell epitopes for cancer immunotherapy. Leukemia. 2007;21(9):1859-1874. (Pubitemid 47299958)
16. Powell DJ Jr, Dudley ME, Robbins PF, Rosenberg SA. Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood. 2005;105(1):241-250.
17. Pule MA, Savoldo B, Myers GD, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008;14(11):1264-1270.
18. Klebanoff CA, Gattinoni L, Torabi-Parizi P, et al. Central memory self-/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci U S A. 2005;102(27):9571-9576. (Pubitemid 40981722)
19. Gattinoni L, Klebanoff CA, Palmer DC, et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest. 2005;115(6):1616-1626. (Pubitemid 40814670)
20. Hinrichs CS, Spolski R, Paulos CM, et al. IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. Blood. 2008;111(11):5326-5333.
21. Mueller K, Schweier O, Pircher H. Efficacy of IL-2- vs IL-15-stimulated CD8 T cells in adoptive immunotherapy. Eur J Immunol. 2008;38(10): 2874-2885.
22. Klebanoff CA, Finkelstein SE, Surman DR, et al. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci U S A. 2004;101(7):1969-1974. (Pubitemid 38228999)
23. Gattinoni L, Zhong XS, Palmer DC, et al. Wnt-signaling arrests effector T cell differentiation and generates CD8(+) memory stem cells. Nat Med. 2009;15(7):808-813.
24. Klebanoff CA, Gattinoni L, Restifo NP. CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol Rev. 2006;211:214-224. (Pubitemid 43882974)
25. Hinrichs CS, Gattinoni L, Restifo NP. Programming CD8+ T cells for effective immunotherapy. Curr Opin Immunol. 2006;18(3):363-370.
26. Wong P, Pamer EG. Cutting edge: antigen-independent CD8 T cell proliferation. J Immunol. 2001;166(10):5864-5868. (Pubitemid 32440707)
27. Kaech SM, Ahmed R. Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naive cells. Nat Immunol. 2001;2(5):415-422. (Pubitemid 33706139)
28. van Stipdonk MJ, Lemmens EE, Schoenberger SP. Naive CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiation. Nat Immunol. 2001;2(5):423-429.
29. van Stipdonk MJ, Hardenberg G, Bijker MS, et al. Dynamic programming of CD8+ T lymphocyte responses. Nat Immunol. 2003;4(4):361-365. (Pubitemid 36432319)
30. Mercado R, Vijh S, Allen SE, Kerksiek K, Pilip IM, Pamer EG. Early programming of T cell populations responding to bacterial infection. J Immunol. 2000;165(12):6833-6839. (Pubitemid 32001151)
31. Prlic M, Hernandez-Hoyos G, Bevan MJ. Duration of the initial TCR stimulus controls the magnitude but not functionality of the CD8+ T cell response. J Exp Med. 2006;203(9):2135-2143. (Pubitemid 44352234)
32. Dalton DK, Pitts-Meek S, Keshav S, Figari IS, Bradley A, Stewart TA. Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. Science. 1993; 259(5102):1739-1742. (Pubitemid 23114658)
33. Huang S, Hendriks W, Althage A, et al. Immune response in mice that lack the interferon-gamma receptor. Science. 1993;259(5102):1742-1745. (Pubitemid 23114659)
34. Weninger W, Crowley MA, Manjunath N, von Andrian UH. Migratory properties of naive, effector, and memory CD8(+) T cells. J Exp Med. 2001;194(7):953-966. (Pubitemid 32953264)
35. Manjunath N, Shankar P, Wan J, et al. Effector differentiation is not prerequisite for generation of memory cytotoxic T lymphocytes. J Clin Invest. 2001;108(6):871-878. (Pubitemid 32880296)
36. Belz GT, Bedoui S, Kupresanin F, Carbone FR, Heath WR. Minimal activation of memory CD8+ T cell by tissue-derived dendritic cells favors the stimulation of naive CD8+ T cells. Nat Immunol. 2007;8(10):1060-1066. (Pubitemid 47423753)
37. Overwijk WW, Surman DR, Tsung K, Restifo NP. Identification of a Kb-restricted CTL epitope of beta-galactosidase: potential use in development of immunization protocols for "self" antigens. Methods. 1997;12(2):117-123.
38. Hwang LN, Yu Z, Palmer DC, Restifo NP. The in vivo expansion rate of properly stimulated transferred CD8+ T cells exceeds that of an aggressively growing mouse tumor. Cancer Res. 2006; 66(2):1132-1138. (Pubitemid 43165982)
39. Zeng R, Spolski R, Finkelstein SE, et al. Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. J Exp Med. 2005;201(1):139-148. (Pubitemid 40130091)
40. Wrzesinski C, Paulos CM, Gattinoni L, et al. Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells. J Clin Invest. 2007;117(2): 492-501. (Pubitemid 46203978)
41. Gattinoni L, Finkelstein SE, Klebanoff CA, et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med. 2005;202(7):907-912. (Pubitemid 41396891)
42. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298(5594):850-854.
43. Palmer DC, Chan CC, Gattinoni L, et al. Effective tumor treatment targeting a melanoma/melanocyte- associated antigen triggers severe ocular autoimmunity. Proc Natl Acad Sci U S A. 2008; 105(23):8061-8066. (Pubitemid 351904708)
44. Lollini PL, Colombo MP, De GC, et al. In vivo reexpression of H-2 antigens in B16 melanoma cells. Exp Clin Immunogenet. 1985;2(1):14-23. (Pubitemid 15105217)
45. Bohm W, Thoma S, Leithauser F, Moller P, Schirmbeck R, Reimann J. T cell-mediated, IFN-gamma- facilitated rejection of murine B16 melanomas. J Immunol. 1998;161(2):897-908. (Pubitemid 28323555)
46. Rivoltini L, Barracchini KC, Viggiano V, et al. Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes. Cancer Res. 1995;55(14):3149-3157.
47. Johnson LA, Morgan RA, Dudley ME, et al. Gene therapy with human and mouse T cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood. 2009; 114(3):535-546.
48. Johnson LA, Heemskerk B, Powell DJ Jr, et al. Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes. J Immunol. 2006;177(9): 6548-6559. (Pubitemid 44628874)
49. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205-216.
50. Levine BL, Bernstein WB, Aronson NE, et al. Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection. Nat Med. 2002;8(1):47-53.
51. Laport GG, Levine BL, Stadtmauer EA, et al. Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation. Blood. 2003;102(6):2004-2013.
52. Porter DL, Levine BL, Bunin N, et al. A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. Blood. 2006;107(4):1325-1331. (Pubitemid 43242365)
53. RapoportAP, Levine BL, Badros A, et al. Molecular remission of CMLafter autotransplantation followed by adoptive transfer of costimulated autologous T cells. Bone Marrow Transplant. 2004;33(1):53-60. (Pubitemid 38159704)
54. Rapoport AP, Stadtmauer EA, Aqui N, et al. Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat Med. 2005;11(11):1230-1237. (Pubitemid 43093671)
55. Rapoport AP, Stadtmauer EA, Aqui N, et al. Rapid immune recovery and graft-vs-host disease-like engraftment-syndrome following adoptive transfer of costimulated autologous T cells. Clin Cancer Res. 2009;15(13):4499-4507.
56. Zhou J, Shen X, Huang J, Hodes RJ, Rosenberg SA, Robbins PF. Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J Immunol. 2005; 175(10):7046-7052. (Pubitemid 41598952)